000276749 001__ 276749
000276749 005__ 20240229155003.0
000276749 0247_ $$2doi$$a10.3390/cancers15102747
000276749 0247_ $$2altmetric$$aaltmetric:150404795
000276749 0247_ $$2pmid$$apmid:37345084
000276749 037__ $$aDKFZ-2023-01130
000276749 041__ $$aEnglish
000276749 082__ $$a610
000276749 1001_ $$aSeidensaal, Katharina$$b0
000276749 245__ $$aPreoperative Dose-Escalated Intensity-Modulated Radiotherapy (IMRT) and Intraoperative Radiation Therapy (IORT) in Patients with Retroperitoneal Soft-Tissue Sarcoma: Final Results of a Clinical Phase I/II Trial
000276749 260__ $$aBasel$$bMDPI$$c2023
000276749 3367_ $$2DRIVER$$aarticle
000276749 3367_ $$2DataCite$$aOutput Types/Journal article
000276749 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1686301969_14894
000276749 3367_ $$2BibTeX$$aARTICLE
000276749 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276749 3367_ $$00$$2EndNote$$aJournal Article
000276749 500__ $$a#LA:E050#
000276749 520__ $$aBackground: To report the final results of a prospective, one-armed, single-center phase I/II trial (NCT01566123). Methods: Between 2007 and 2017, 37 patients with primary or recurrent (N = 6) retroperitoneal sarcomas were enrolled. Treatment included preoperative IMRT of 45–50 Gy with a simultaneous integrated boost of 50–56 Gy, surgery and IORT. The primary endpoint was local control (LC) at 5 years. The most common histology was dedifferentiated liposarcoma (51%), followed by leiomyosarcoma (24%) and well-differentiated liposarcoma (14%). The majority of lesions were high-grade (FNCLCC G1: 30%, G2: 38%, G3: 27%, two missing). Five patients were excluded from LC analysis per protocol. Results: The minimum follow-up of the survivors was 62 months (median: 109; maximum 162). IORT was performed for 27 patients. Thirty-five patients underwent gross total resection; the pathological resection margin was mostly R+ (80%) and, less often, R0 (20%). We observed 10 local recurrences. The 5-year LC of the whole cohort was 59.6%. Eleven patients received a dose > 50 Gy plus IORT boost; LC was 64.8%; the difference, however, was not significant (p = 0.588). Of 37 patients, 15 were alive and 22 deceased at the time of final analysis. The 5-year OS was 59.5% (68.8% per protocol). Conclusions: The primary endpoint of a 5-year LC of 70% was not met. This might be explained by the inclusion of recurrent disease and the high rate of G3 lesions and leiomyosarcoma, which have been shown to profit less from radiotherapy. Stratification by grading and histology should be considered for future studies.
000276749 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000276749 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000276749 7001_ $$aDostal, Matthias$$b1
000276749 7001_ $$aKudak, Andreas$$b2
000276749 7001_ $$aJaekel, Cornelia$$b3
000276749 7001_ $$00000-0001-7087-9581$$aMeixner, Eva$$b4
000276749 7001_ $$aLiermann, Jakob$$b5
000276749 7001_ $$aWeykamp, Fabian$$b6
000276749 7001_ $$aHoegen, Philipp$$b7
000276749 7001_ $$aMechtersheimer, Gunhild$$b8
000276749 7001_ $$aWillis, Franziska$$b9
000276749 7001_ $$aSchneider, Martin$$b10
000276749 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b11$$eLast author$$udkfz
000276749 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15102747$$gVol. 15, no. 10, p. 2747 -$$n10$$p2747$$tCancers$$v15$$x2072-6694$$y2023
000276749 909CO $$ooai:inrepo02.dkfz.de:276749$$pVDB
000276749 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000276749 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000276749 9141_ $$y2023
000276749 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-24T07:56:58Z
000276749 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000276749 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000276749 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000276749 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000276749 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000276749 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000276749 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000276749 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000276749 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000276749 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000276749 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000276749 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000276749 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000276749 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000276749 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000276749 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000276749 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000276749 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000276749 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000276749 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000276749 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000276749 980__ $$ajournal
000276749 980__ $$aVDB
000276749 980__ $$aI:(DE-He78)E050-20160331
000276749 980__ $$aI:(DE-He78)HD01-20160331
000276749 980__ $$aUNRESTRICTED